A long-acting Factor VIII replacement therapy for haemophilia A from Sobi and Sanofi has been recommended for use by the NHS ...

NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in ...

Pfizer has ended the global commercialisation of its haemophilia B (factor IX deficiency) gene therapy Beqvez, citing soft ...

Dosing is based on the person’s weight and the treatment at list price would cost around £510,000 per year for an adult ...

Haemophilia, a rare blood disorder affecting clotting, is one such condition that can manifest early in life. It’s essential to understand haemophilia. Simply put, haemophilia is a condition ...

Haemophilia, a rare blood disorder affecting clotting, is one such condition that can manifest early in life. It’s a ...

HIBISCUS phase 2 data evaluating the safety profile and efficacy of etavopivat in adult and adolescent patients with sickle cell disease FRONTIER4 interim phase 3 results evaluating safety profile and ...

Alison Dawson-Meadows, who works for United Lincolnshire Teaching Hospitals NHS Trust, was given the honour by The Haemophilia Society. Ms Dawson-Meadows is part of a team that supports 600 ...

Haemophilia is a rare genetic bleeding disorder that causes the blood to take a long time to clot because of a deficiency in one or several blood clotting factors. It is almost exclusively found ...

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low demand and interest. A Pfizer spokesperson told Pharmaceutical Technology in ...